Drug Profile
Simotinib
Alternative Names: AL-6802; SIM-6802; Simotinib hydrochloride; XimotiniLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Advenchen Laboratories
- Developer Advenchen Laboratories; Simcere Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
- 02 Jun 2017 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
- 15 Apr 2016 Chemical structure information added